Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Cancer Genomics and Diagnostics, Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, and Genomics and Rare Diseases.
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
<i>TET2</i>-Driven Clonal Hematopoiesis and Response to Canakinumab
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Association of <i>MTOR</i> Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism
Genome-wide association study and admixture mapping reveal new loci associated with total IgE levels in Latinos
Whole-Genome Sequencing of Individuals from a Founder Population Identifies Candidate Genes for Asthma
Properties and rates of germline mutations in humans
Estimating the human mutation rate using autozygosity in a founder population